PriceTargets.com logo

NASDAQ:BIVI - BioVie Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $13.50
  • Forecasted Upside: 431.50 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.54 As of 05/25/2022 01:00 AM ET
▲ +0.02 (0.79%)

This chart shows the closing price for BIVI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BioVie Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BIVI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BIVI

Analyst Price Target is $13.50
▲ +431.50% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for BioVie in the last 3 months. The average price target is $13.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 431.50% upside from the last price of $2.54.

This chart shows the closing price for BIVI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in BioVie.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/1/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/1/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/14/2022OppenheimerInitiated CoverageOutperform$9.00Low
1/24/2022B. RileyLower Price Target$27.00 ➝ $18.00High
11/30/2021B. RileyLower Price TargetBuy$50.00 ➝ $27.00High
7/23/2021B. RileyReiterated RatingBuy$50.00High
5/25/2021B. RileyBoost Price TargetBuy$47.00 ➝ $50.00High
1/15/2021B. RileyInitiated CoverageBuy$47.00High
(Data available from 5/25/2017 forward)

News Sentiment Rating

0.07 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/24/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2022

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
BioVie logo
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Santa Monica, California.
Read More

Today's Range

Now: $2.54
Low: $2.50
High: $2.58

50 Day Range

MA: $3.85
Low: $2.52
High: $5.04

52 Week Range

Now: $2.54
Low: $2.50
High: $19.10

Volume

18,131 shs

Average Volume

44,620 shs

Market Capitalization

$63.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

Frequently Asked Questions

What sell-side analysts currently cover shares of BioVie?

The following Wall Street analysts have issued research reports on BioVie in the last year: B. Riley, Oppenheimer Holdings Inc., and Zacks Investment Research.
View the latest analyst ratings for BIVI.

What is the current price target for BioVie?

0 Wall Street analysts have set twelve-month price targets for BioVie in the last year. Their average twelve-month price target is $13.50, suggesting a possible upside of 431.5%.
View the latest price targets for BIVI.

What is the current consensus analyst rating for BioVie?

BioVie currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BIVI will outperform the market and that investors should add to their positions of BioVie.
View the latest ratings for BIVI.

How do I contact BioVie's investor relations team?

The company's listed phone number is (312) 283-5793 and its investor relations email address is [email protected] The official website for BioVie is www.biovieinc.com. Learn More about contacing BioVie investor relations.